Market news

BioMarin Pharmaceutical Inc. stock outlook: Q4 2026–2027 catalysts, DMD BMN 351 data, Voxzogo approval potential, and raised guidance. Click for this BMRN update.

BioMarin Pharmaceutical (BMRN) has been in focus after appointing Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee, sharpening attention on how governance aligns with the rare-disease portfolio. Recent trading has been choppy for BioMarin Pharmaceutical, with the share price down 7.77% over 30 days, even after a 16.91% 90 day share price return and a 17.62% total shareholder return over the past year. This points to momentum cooling in the short term despite...

BioMarin Pharmaceutical recently reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug’s use, while also adding Bristol Myers Squibb research leader Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee. The combination of strong late-stage VOXZOGO data in an indication with no approved treatments and the addition of a seasoned R&D executive to the board underscores...

BioMarin Pharmaceutical (NASDAQ:BMRN) said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BioMarin Pharmaceutical (BMRN) stock drops as the company ends studies for dwarfism therapy Voxzogo in Noonan syndrome. Read more here.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective September 10, 2026.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis’s achondroplasia drug Yuviwel. The settlement resolves litigation currently pending in numerous jurisdictions, including a Section 337 investigation by the US International […]

Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan.Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The achondroplasia market across the seven major markets-the United States, G

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia were published in New England Journal of Medicine (NEJM) Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting. The data included new results on the magnitude of benefit seen in children receiving VOXZOGO, including statistically significant improvements in annualized growth ve

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will receive royalties equal to 20% of U.S. Yuviwel net […]

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.

Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Alesta Therapeutics. The acquisition will strengthen BioMarin's skeletal conditions portfolio, adding ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene. ALE1 is currently being evaluated in an ongoing Phase 1/2a clinical trial assessing safety, tolerability and pharmacokinetics/pha

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel. Ascendis Pharma’s Yuviwel (navepegritide, developed as TransCon CNP) is a once-weekly prescription injection approved by the FDA to increase linear height growth in children aged 2 years and older with achondroplasia who have open growth plates. In March, the FDA approved Yuviwel, the first and only once-w

COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. (“BioMarin”) related to the sale of YUVIWEL® and navepegritide-related products. The binding term sheet provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies. Under the terms, BioMarin has agreed to gr

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International Trade Commission (ITC) concerning Ascendis's Yuviwel. As part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Kor

BioMarin Pharmaceutical (NasdaqGS:BMRN) agreed to acquire Alesta Therapeutics for up to US$490 million to expand its rare disease portfolio. The deal centers on ALE1, an oral small molecule candidate being developed as a potential first oral therapy for hypophosphatasia, a rare genetic bone disorder. BioMarin expects the acquisition to add an oral rare bone disease program to its clinical pipeline and to support its future growth plans. For readers looking to compare BioMarin with other...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with BioMarin Pharmaceutical (NASDAQ:BMRN).

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alesta Therapeutics, a clinical-stage biotech company.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expanding its rare-disease business with the acquisition of Alesta Therapeutics for $275 million upfront. The deal gives BioMarin access to ALE1, an oral treatment being developed for hypophosphatasia (HPP), a rare genetic bone disorder. ALE1 is still in early-stage clinical trials, so there is a long way to go before […]

BMO starts BioMarin at outperform, saying Voxzogo erosion fears are overdone. Read more here.

The deal gives BioMarin access to ALE1, a small-molecule drug in early-stage trials that could become the first oral therapy for hypophosphatasia

BioMarin will acquire Alesta Therapeutics for $275 million upfront, bolstering BioMarin's unit focused on rare skeletal conditions.

The deal provides BioMarin with a potential rival to AstraZeneca’s blockbuster Strensiq in hypophosphatasia.

BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.